Publications by authors named "M Lowdell"

Claim this Profile
D
Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases.
Lindsay C Davies, Lucie Biard, Damián García-Olmo, Gary Gilkeson, Massimiliano Gnecchi, Mark W Lowdell

Cytotherapy· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
Claire Roddie, Juliana Dias, Maeve A O'Reilly, Mahnaz Abbasian, Amaia Cadinanos-Garai, Mark W Lowdell

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines.
Jonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, Anucha Preechanukul, Noshin Hussain, Mark W Lowdell

Cytotherapy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines.
Jonida Kokiçi, Helena Arellano-Ballestero, Benjamin Hammond, Anucha Preechanukul, Noshin Hussain, Mark W Lowdell

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system.
Aine O'Sullivan, Sarah Case, Aisling McCrudden, Emer Hackett, Louise Gallagher, Mark W Lowdell

Mol Ther Methods Clin Dev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis